Match constipation therapy to stool water, secretion, propulsion, or outlet dysfunction, with current drug indications, dosing, and safety distinctions.
Soft stool that will not pass is a different problem from dry stool that needs water. Before adding another laxative, decide whether the limiting factor is stool consistency, colonic propulsion, pain associated with IBS-C, or coordination at the outlet.
Vomiting, progressive distention, severe pain, and obstipation change the task. Evaluate suspected obstruction before routine oral laxative escalation.
Find the limiting factor before choosing the drug
Constipation includes hard stool, infrequent passage, straining, incomplete evacuation, and difficult expulsion. A stool-frequency number alone does not identify the mechanism. Review the onset, stool form, pain, medication changes, fiber intake, mobility, and secondary causes. Opioids, anticholinergics, iron, and calcium are common contributors. New bleeding, anemia, weight loss, a mass, or an abrupt unexplained change requires evaluation rather than routine escalation. [1][2]
Chronic idiopathic constipation, or CIC, is not synonymous with irritable bowel syndrome with constipation, or IBS-C. Recurrent abdominal pain associated with defecation or altered stool pattern is central to IBS. A drug can improve stool frequency without adequately treating the pain component. Conversely, a person with little pain and hard stool does not automatically have IBS-C and should not receive an IBS-C-specific drug solely because constipation is present. [3]
Slow transit describes delayed colonic passage. A defecatory disorder describes impaired evacuation, often from inappropriate pelvic-floor or anal coordination during attempted defecation. These can coexist. A patient needing digital maneuvers to pass already-soft stool deserves outlet assessment. The 2026 AGA update emphasizes anorectal manometry, balloon expulsion testing, and indicated biofeedback before labeling most patients as refractory. [2]
Lumen
Psyllium holds water in bulk. PEG retains water osmotically. Docusate changes stool surface tension.
Apical epithelium
Lubiprostone promotes chloride secretion. GC-C agonists increase cyclic GMP and CFTR secretion. Tenapanor reduces sodium absorption through NHE3 inhibition.
Enteric motor signaling
Prucalopride activates 5-HT4 signaling and supports propulsive colonic contractions.
Anorectal outlet
Biofeedback retrains evacuation coordination when dyssynergia is established. Increasing luminal water alone does not correct the coordination defect.
Compare targets simultaneously. A luminal treatment can soften stool while an outlet problem remains unresolved.
Bulk, retained water, and stimulation are different tools
Psyllium adds hydrated bulk
For a patient with low dietary fiber and no obstructive or swallowing concern, psyllium is a reasonable initial option. Adequate fluid is essential: the reviewed psyllium powder instructions require at least 8 ounces (240 mL) with each dose. Introduce it with attention to bloating and adherence. Fiber is not an instruction to drink without limit when a patient has a prescribed fluid restriction; individualize the plan. Psyllium is poorly suited to suspected obstruction, significant narrowing, dysphagia, or a patient unable to take the required liquid safely. [1][11]
PEG retains water without bacterial fermentation
Polyethylene glycol is an osmotic laxative with strong guideline support for adult CIC. It is often a practical choice after inadequate fiber response. A common adult regimen is PEG 3350, 17 g once daily, adjusted to effect. This everyday regimen is different from the large-volume solutions used for bowel preparation. Excess effect can still cause diarrhea or bloating; dose and formulation matter. [1]
Lactulose also retains luminal water but is fermented by colonic bacteria, so gas and bloating can limit tolerability. Magnesium salts are osmotic agents with an additional systemic risk when renal clearance is impaired. The CIC guideline suggests magnesium oxide with caution and advises avoiding it in renal insufficiency because of hypermagnesemia risk. “Osmotic” is a mechanism family, not a guarantee that every member has identical safety. [1]
Stimulants add secretion and propulsion
Bisacodyl, sodium picosulfate, and senna can produce cramping, urgency, or diarrhea. Bisacodyl or sodium picosulfate has strong guideline support for short-term use or rescue; senna has a conditional recommendation. Longer supervised use may be reasonable, although long-term evidence is less complete. Do not convert that evidence limitation into a blanket claim that every appropriately used stimulant inevitably damages the colon. Start with a dose the patient can tolerate and reassess the actual response. [1]
Docusate is a surfactant stool softener. Its familiar name should not be confused with strong evidence for established chronic constipation. It was not supported by adequate data for a substantive recommendation in the 2023 CIC guideline. A randomized hospice trial found no meaningful benefit from adding docusate to sennosides in that studied population. This does not prove zero benefit in every setting; it does argue against reflexively treating it as the most effective default. [1][10]
Secretion and sodium absorption offer different prescription targets
Lubiprostone is described in its label as a locally acting chloride-channel activator, with ClC-2-mediated chloride-rich secretion. Water follows into the lumen. Adult CIC and opioid-induced constipation associated with chronic noncancer pain use 24 mcg twice daily; the OIC indication also includes pain related to prior cancer or its treatment when frequent opioid-dose escalation is not required. IBS-C in women aged at least 18 years uses 8 mcg twice daily. Take it with food and water to reduce nausea. Severe diarrhea, suspected obstruction, and hepatic impairment require attention to the label's restrictions and dosing guidance. Effectiveness for opioid-induced constipation with methadone has not been established. [4]
Linaclotide and plecanatide activate guanylate cyclase-C on the intestinal epithelium. Increased intracellular cyclic GMP promotes CFTR-mediated chloride and bicarbonate secretion, increasing water and transit. Their shared receptor does not make their doses, food instructions, or pediatric restrictions identical. For adults with CIC who do not respond to OTC agents, the 2023 guideline strongly recommends linaclotide or plecanatide; lubiprostone has a conditional recommendation. IBS-C has its own evidence assessment: the 2022 AGA guideline strongly recommends linaclotide and conditionally recommends plecanatide, tenapanor, and lubiprostone. These strengths do not establish a head-to-head efficacy ranking. [1][3] Severe diarrhea calls for suspending treatment and rehydration. [5][6]
Read the age and indication together
Linaclotide, May 2026 label has adult CIC and IBS-C indications, IBS-C from age 7, and pediatric functional constipation from age 2. It is contraindicated below age 2. Adult IBS-C uses 290 mcg daily; pediatric IBS-C uses 145 mcg daily; pediatric functional constipation uses 72 mcg daily. Adult CIC uses 145 mcg or 72 mcg daily according to presentation and tolerability.
Plecanatide is labeled for adult CIC and IBS-C at 3 mg daily. It is contraindicated below age 6 and should be avoided from age 6 to under 18. Its pediatric restriction must not be copied onto linaclotide or vice versa.
Linaclotide is taken on an empty stomach at least 30 minutes before a meal; plecanatide may be taken with or without food. Both require a patent gastrointestinal lumen. The clinical indication and tolerability determine selection, not a numerical comparison between milligrams and micrograms of different molecules. [5][6]
Tenapanor inhibits the sodium/hydrogen exchanger NHE3 at the apical intestinal surface. Less sodium is absorbed, so more sodium and water remain in the lumen. IBSRELA is indicated for adult IBS-C at 50 mg twice daily immediately before breakfast or the first meal and dinner. It is not a 5-HT4 prokinetic or a direct ammonia binder. The label contraindicates use below age 6, advises avoidance from age 6 to under 12, and states that pediatric safety and effectiveness below 18 are unestablished. Severe diarrhea requires suspension and rehydration. [7]
Propulsion can improve while evacuation still fails
Prucalopride is a selective 5-HT4 agonist for adult CIC. It promotes enteric signaling and colonic high-amplitude propagating contractions. It is a guideline-supported option after inadequate response to OTC agents, including in an appropriate slow-transit presentation. A normal outlet assessment helps avoid attributing every difficult evacuation to weak colonic propulsion. [1][8]
Prucalopride is contraindicated with intestinal perforation or obstruction, obstructive ileus, and severe inflammatory intestinal conditions such as Crohn disease, ulcerative colitis, or toxic megacolon/megarectum. The usual adult dose is 2 mg once daily. Severe renal impairment with creatinine clearance below 30 mL/min requires 1 mg once daily; avoid use in end-stage renal disease requiring dialysis. Headache, nausea, abdominal pain, and diarrhea are common adverse effects. The label also requires monitoring for new or worsening depression or suicidal thoughts and behavior, with immediate discontinuation and contact with the clinician if these emerge. A causal relationship has not been established; that uncertainty does not cancel the warning. [8]
Documented dyssynergic defecation needs pelvic-floor biofeedback rather than endless additions of secretagogues. Soft stool, prolonged straining, incomplete evacuation, and abnormal balloon expulsion can point toward this problem. Drug treatment may still help stool consistency, but it does not teach coordinated relaxation during evacuation. Reassess a failed regimen by asking what improved and what did not. [2]
Lactulose has an additional role in hepatic encephalopathy
In cirrhosis with hepatic encephalopathy, bacterial fermentation of lactulose acidifies colonic contents. Lower pH favors conversion of diffusible NH3 to less readily absorbed NH4+, and increased stool passage increases fecal nitrogen elimination. This is a colon-mediated effect, not direct binding of ammonia in blood. Docusate and tenapanor do not reproduce this established therapeutic role. [9]
For maintenance after an overt episode, titrate lactulose toward two to three soft stools daily while following the clinical state. More watery stool is not necessarily more benefit. Excess dosing can cause dehydration and electrolyte problems that themselves precipitate encephalopathy. Evaluate infection, gastrointestinal bleeding, sedatives, constipation, and other triggers; do not treat only a serum ammonia value. Acute encephalopathy also requires assessment of airway safety and the appropriate route of treatment. [9]
Define success before adding the next agent
Use a measurable goal such as comfortable passage of soft formed stool, less straining, or improvement in the abdominal pain and bowel pattern of IBS-C. Medication administration frequency is not the same as a stool target. PEG, linaclotide, plecanatide, and prucalopride commonly use once-daily regimens; lubiprostone and tenapanor use twice-daily regimens for the indications described here. Lactulose for encephalopathy is titrated to clinical response and stool consistency. [1][4][7][9]
Review renal function, hydration, age, comorbidities, and current stool consistency before escalation. New severe diarrhea means assess volume and electrolytes and suspend the responsible secretory drug when indicated. New vomiting and distention means reconsider obstruction. Persistent difficult passage of soft stool means reconsider the outlet. An adverse effect or a diagnostic mismatch should not automatically be answered with another prescription.
Low fiber with safe swallowing suggests hydrated bulk. Persistent hard stool suggests a retained-water strategy. IBS-C pain may justify an indication-specific epithelial agent. Refractory CIC may justify secretion or 5-HT4 therapy. An abnormal outlet needs retraining. Suspected obstruction needs evaluation.
Choose the mechanism that fits
Case 1
Show answer and explanations for case 1
A. Psyllium with adequate liquid (Best answer)
Hydrated bulk addresses low fiber in a patient without obstructive or swallowing concerns.
B. Begin tenapanor (Why this does not fit)
Tenapanor is indicated for adult IBS-C; this low-fiber history without a recurrent pain phenotype does not establish that indication.
C. Use docusate alone (Why this does not fit)
Docusate does not correct low fiber as directly and lacks the supporting CIC evidence of other commonly used agents.
D. Begin prucalopride (Why this does not fit)
Prucalopride is supported after inadequate response to OTC therapy; this modifiable low-fiber contributor has not yet been addressed.
Takeaway: Choose a low-complexity treatment that matches the phenotype.
This has an adult IBS-C indication, whereas the clinical question is established CIC without a prominent pain phenotype.
B. Lactulose (Why this does not fit)
Lactulose is an option after failure or intolerance of other OTC therapies but has a conditional recommendation, unlike the strong recommendation for PEG.
C. Polyethylene glycol (Best answer)
PEG is a strongly recommended osmotic therapy for adult CIC.
D. Docusate (Why this does not fit)
A familiar stool softener does not have the supporting CIC trial evidence needed to match PEG in this question.
Takeaway: After inadequate fiber response, a retained-water strategy can fit CIC.
A. IBSRELA is contraindicated below age 6 because of serious dehydration risk (Best answer)
Minimal systemic exposure does not prevent harmful intestinal fluid loss.
B. Use a reduced adult IBSRELA dose because there is little systemic absorption (Why this does not fit)
Local intestinal water loss can cause serious dehydration and the age-specific contraindication still applies.
C. Apply the linaclotide pediatric age boundary to IBSRELA (Why this does not fit)
These are different drugs with different labeled pediatric indications and restrictions.
D. Treat age 6 as the only pediatric restriction to remember (Why this does not fit)
In addition to the contraindication below 6, the label advises avoidance from 6 to under 12 and states pediatric effectiveness below 18 is unestablished.
Takeaway: Local drug action can still create systemic harm.
